Overview

Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

Status:
Active, not recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 Positive adenocarcinoma at gastroesophageal junction

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Medical University

Treatments:

Capecitabine
Oxaliplatin
Trastuzumab